激光联合玻璃体腔注射康柏西普治疗糖尿病性视网膜病变的疗效观察
Clinical Observation of Laser Combined with Intravitreal Injection of Conbercept in the Treatment of Diabetic Retinopathy
DOI: 10.12677/HJO.2016.54019, PDF, HTML, XML, 下载: 1,642  浏览: 3,257 
作者: 徐 丹, 秦 梅：蚌埠医学院第一附属医院眼科，安徽 蚌埠
关键词: 全视网膜激光光凝；康柏西普；糖尿病视网膜病变；黄斑水肿；Panretinal Photocoagulation； Conbercept； Diabetic Retinopathy； Macular Edema
摘要: 目的：观察视网膜光凝联合玻璃体腔内注射康柏西普的临床疗效及安全性。方法：选择自2015年9月至2016年7月就诊于我院眼科的糖尿病性视网膜病变患者，共17人25只眼，每月1次在手术室内进行玻璃体腔注射康柏西普，共2~3次。首次注药1周后，开始门诊分期完成全视网膜光凝术。随访患者治疗前、联合治疗后第1周、第1个月，第3个月时的最佳矫正视力、黄斑区视网膜厚度和黄斑区体积的改变，进行统计学分析，观察疗效。结果：患者黄斑区总体积及视网膜平均厚度、中心厚度在术后1月、3月时较术前有不同程度下降，差异均有统计学意义(P < 0.05)，视力较术前提高(P < 0.05)。结论：全视网膜激光光凝联合康柏西普可以有效改善糖尿病黄斑水肿，提高患者视力，安全有效。
Abstract: Objective: To observe the clinical efficacy and safety of retinal photocoagulation combined with intravitreal injection of Conbercept. Methods: 25 eyes (17 patients) with diabetic retinopathy who were treated by our hospital from September 2015 to July 2016 were treated with intravitreal in-jection of Conbercept once a month, a total of 2 - 3 times. One week after the first injection, panretinal photocoagulation was performed in outpatient staging. The best corrected visual acuity, macular retinal thickness and macular volume were observed before and the first week, the first month and the third month after laser treatment, and the curative effect was analyzed by statistical analysis. Results: The total volume of the retina in the macular region and the mean retinal thickness, central thickness were significantly decreased at the first month and the third month after laser treatment compared with the preoperative level, the difference was statistically significant (P < 0.05). Patients with visual acuity improved compared with preoperative level (P < 0.05). Conclusion: Panretinal photocoagulation combined with Conbercept can effectively improve diabetic macular edema and visual acuity, and it is safe and effective.
文章引用：徐丹, 秦梅. 激光联合玻璃体腔注射康柏西普治疗糖尿病性视网膜病变的疗效观察[J]. 眼科学, 2016, 5(4): 109-114. http://dx.doi.org/10.12677/HJO.2016.54019

参考文献

[1] 李筱荣, 黎晓新, 惠延年. 糖尿病眼病[M]. 北京: 人民卫生出版社, 2010: 131.
[2] Lally, D.R., Shah, C.P. and Heier,J .S. (2016) Vascular Endothelial Growth Factor and Diabetic Macular Edema. Survey of Ophthalmology, 61, 759-768. https://doi.org/10.1016/j.survophthal.2016.03.010
[3] Stewart, M.W. (2016) Treatment of Diabetic Retinopathy: Recent Advances and Unresloved Challenges. World Journal of Diabetes, 7, 333-341. https://doi.org/10.4239/wjd.v7.i16.333
[4] Crawford, T.N., Rd, A.D., Kerrison, J.B., et al. (2009) Diabetic Retinopathy and Angiogenesis. Current Diabetes Reviews, 5, 8-13. https://doi.org/10.2174/157339909787314149
[5] Bringmann, A., Reichenbach, A. and Wiedemann, P. (2004) Pathomechanisms of Cystoid Macular Edema. Ophthalmic Research, 36, 241-249. https://doi.org/10.1159/000081203
[6] Joussen, A.M., Murata, T., Tsujikawa, A., et al. (2001) Leukocyte-Mediated Endothelial Cell Injury and Death in the Diabetic Retina. American Journal of Pa-thology, 158, 147-152. https://doi.org/10.1016/S0002-9440(10)63952-1
[7] Shimizu, E., Funatsu, H., Yamashita, H., et al. (2002) Plasma Level of Interleukin-6 Is an Indicator for Predicting Diabetic Macular Edema. Japanese Journal of Ophthalmology, 46, 78-83. https://doi.org/10.1016/S0021-5155(01)00452-X
[8] Huang, D., Swanson, E.A., Lin, C.P., et al. (1991) Optical Coherence To-mography. Science, 254, 1178-1181. https://doi.org/10.1126/science.1957169
[9] 霍鸣, 张海江, 吴昊等. 糖尿病视网膜病变的激光光凝治疗[J]. 国际眼科杂志, 2007, 7(1): 202-203.
[10] 崔浩, 王宁利. 眼科学[M]. 北京: 人民卫生出版社, 2014: 118-122.
[11] Henricsson, M. and Heijl, A. (1994) The Effect of Panretinal Laser Photocoagulation on Visual Acuity, Visual Fields and on Subjective Visual Impairment in Preproliferative and Early Proliferative Diabetic Retinopathy. Acta Ophthalmologica, 72, 570-575. https://doi.org/10.1111/j.1755-3768.1994.tb07181.x
[12] Mackie, S.W. and Walsh, G. (1998) Contrast and Glare Sensitivity in Dia-betic Patients with and without Pan-Retinal P-Hotocoagulation. Ophthalmic & Physiological Optics, 18, 173-181. https://doi.org/10.1016/S0275-5408(97)00083-5
[13] Early Treatment of Diabetic Retinopathy Study Research Group (1991) Early Photocoagulation for Diabetic Retinopathy. Ophthalmology, 98, 766-785. https://doi.org/10.1016/S0161-6420(13)38011-7
[14] Ferrara, N. (2013) Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocrine Reviews, 25, 581-611. https://doi.org/10.1210/er.2003-0027
[15] Reis-Filho, J.S. and Tutt, A.N.J. (2008) Triple Negative Tumours: A Critical Review. Histopathology, 52, 108-118. https://doi.org/10.1111/j.1365-2559.2007.02889.x
[16] Schmucker, C., Ehlken, C., Hansen, L.L., et al. (2011) Intravitreal Bevaci-zumab (Avastin) vs. Ranibizumab (Lucentis) for the Treatment of Age-Related Macular Degeneration: A Systematic Review. British Journal of Ophthalmology, 95, 308-317. https://doi.org/10.1136/bjo.2009.178574
[17] 孙丽丽, 季拓. 贝伐单抗联合全视网膜光凝治疗增生型糖尿病视网膜病变的疗效观察[J]. 眼科新进展, 2016, 36(10): 949-952.
[18] Andreoli, C.M. and Miller, J.W. (2007) Anti-Vascular Endothelial Growth Factor Therapy for Ocular Neovascular Disease. Current Opinion in Ophthalmology, 18, 502-508. https://doi.org/10.1097/ICU.0b013e3282f0ca54
[19] Wang, Q., Li, T., Wu, Z., et al. (2013) Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGF Isoforms Provide Remarkable Anti-Angiogenesis Effect in Vivo. PLOS ONE, 8, e70544. https://doi.org/10.1371/journal.pone.0070544
[20] 方明喜, 吴彬彬, 贾海镜. 玻璃体内注射贝伐单抗联合视网膜激光光凝治疗糖尿病性黄斑水肿[J]. 国际眼科杂志, 2016, 16(5): 909-911.

为你推荐